BioSyent Inc. said it will report consolidated financial results for the three and six months ended June 30, 2026 on Thursday, Aug. 13, 2026 after market hours. A presentation on the company’s second-quarter and first-half 2026 results by Rene Goehrum, BioSyent President and CEO, will be made available on the company’s website on the date of release. BioSyent, which trades on the TSX Venture Exchange under the symbol RX, describes itself as a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing pharmaceutical and oral health products in Canada and internationally. The company said it had 11,312,635 common shares outstanding as of the date of the press release.